A pharmacist by training, Dr. Nicolas Bertrand is an assistant professor at Laval University’s School of Pharmaceutical Studies. He is also a researcher in the department of Endocrinology and Nephrology at the CHU de Quebec Research Center. His research in nanomedicine focuses on potentiating the efficacy of therapeutic molecules by using nanotechnologies. He is the editor of the European Journal of Pharmaceutics and Biopharmaceutics (Elsevier, IF: 4.2) and director of the « Biopharmacy et pharmacometrics » strategic cluster of the Réseau Québécois de Recherche sur les Médicaments (rqrm.ca). He is an associate member of the Institute on Nutraceuticals and Functional Foods (INAF) and of the Centre de Recherche sur les Matériaux Avancés (CERMA).

Encapsulating bioactive molecules through differentiated technologies

Many drugs in development, or already on the market, possess suboptimal physiochemical or pharmacological characteristics. Nanomedicine can harness the unique features of nanomaterials to facilitate the administration of these drugs, or potentiate their efficacy. Encapsulation of bioactive molecules in nanoparticles can prevent their metabolism, ameliorate their pharmacokinetics, or ensure their optimal distribution to diseased tissues. Altogether, these effects can pave the way for more efficient and better tolerated drugs.

Dr. Nicolas Bertrand’s laboratory uses functional polymers and lipids to encapsulate a variety of bioactive molecules in clinically-relevant drug delivery vehicles.

Elucidate the interactions of nanomaterials with the immune system

Like other drugs, the use of nanoparticles as drug delivery vehicles can trigger unexpected or undesirable reactions. The type of system, its size, or the materials used in its preparation can all influence the nature and extent of its interactions with the immune system. The development of better tolerated nanomedicines necessitates a better understanding of how drug delivery platforms interact with the various components of the immune system.

Through a unique expertise in the preparation of nanoparticle libraries, combined with an established knowledge in preclinical pharmacokinetics, Dr. Nicolas Bertrand’s laboratory specialises in studying the fate of nano- and biomaterials in living animals. This approach leads to an integrated understanding of the interactions of materials with complete, functional biological systems.

CHUL
2705, boulevard Laurier
T-4-13
Québec, Québec
Canada G1V 4G2
30 entries « 2 of 3 »

Bertrand N, Simard P, Leroux JC

Serum-Stable, Long-Circulating, pH-Sensitive PEGylated Liposomes.

Journal Article

Methods Mol Biol, 1522 , pp. 193-207, 2017, ISSN: 1064-3745.

Abstract | Links:

Mahmoudi M, Bertrand N, Zope H, Farokhzada OC

Emerging understanding of the protein corona at the nano-bio interfaces

Journal Article

Nano Today, 11 (6), pp. 817-832, 2016, ISSN: 1748-0132.

| Links:

Wu J, Zhao L, Xu X, Bertrand N, Choi WI, Yameen B, Shi J, Shah V, Mulvale M, MacLean JL, Farokhzad OC

Hydrophobic Cysteine Poly(disulfide)-based Redox-Hypersensitive Nanoparticle Platform for Cancer Theranostics.

Journal Article

Angew Chem Int Ed Engl, 54 (32), pp. 9218-23, 2015, ISSN: 0570-0833.

Abstract | Links:

Brandl F, Bertrand N, Lima EM, Langer R

Nanoparticles with photoinduced precipitation for the extraction of pollutants from water and soil.

Journal Article

Nat Commun, 6 , pp. 7765, 2015, ISSN: 2041-1723.

Abstract | Links:

Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O

Cancer nanomedicine: from targeted delivery to combination therapy.

Journal Article

Trends Mol Med, 21 (4), pp. 223-32, 2015, ISSN: 1471-4914.

Abstract | Links:

Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM

Engineered nanomedicine for myeloma and bone microenvironment targeting.

Journal Article

Proc Natl Acad Sci U S A, 111 (28), pp. 10287-92, 2014, ISSN: 0027-8424.

Abstract | Links:

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

Journal Article

Adv Drug Deliv Rev, 66 , pp. 2-25, 2014, ISSN: 0169-409X.

Abstract | Links:

Lim JM, Bertrand N, Valencia PM, Rhee M, Langer R, Jon S, Farokhzad OC, Karnik R

Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study.

Journal Article

Nanomedicine, 10 (2), pp. 401-9, 2014, ISSN: 1549-9634.

Abstract | Links:

Bertrand N, Collin P, Ranger M, Leblond J

Designing polymeric binders for pharmaceutical applications

Book Chapter

HJ, Schneider (Ed.): Supramolecular Systems in Biomedical Fields, pp. 483-517 , Cambridge, RSC Publishing, 2013, ISBN: 9781849736589.

| Links:

Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC

Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Journal Article

Adv Drug Deliv Rev, 64 (13), pp. 1363-84, 2012, ISSN: 0169-409X.

Abstract | Links:

30 entries « 2 of 3 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche sur les matériaux avancés, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2025-04-30
  • Designing quality control strategies to assess the self-assembly and biological stability of chitosan nanoparticles, Partenariat, MITACS Inc., Accélération Québec (MITACS et gouvernement provincial), from 2018-05-01 to 2021-06-30
  • Engineering functional nanoparticles using libraries of polymers, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
  • Envisager une protection contre le passage des perturbateurs endocriniens à travers la peau, Subvention, Fondation de l'Université Laval, from 2019-02-01 to 2020-12-31
  • Nanopharmacologie et nanomédecine : vers le développement de plates-formes technologiques pour la vectorisation des médicaments, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2018-07-01 to 2022-06-30
  • Nanopharmacologie et nanomédecine: vers le développement de plates-formes technologiques pour la vectorisation des médicaments, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2018-07-01 to 2022-06-30
  • Prevention of glioblastoma recurrence by injection in the resection cavity of a hydrogel formed by targeted lipid nanocapsules loaded with anticancer drugs, GLIOGEL, Subvention, Fonds de recherche du Québec - Santé, ERA-NET EuroNanoMed, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Évaluation de l'impact de nanoparticules liposomales sur l'efficacité in vivo du transport intracellulaire de protéines vectorisées par la plateforme Feldan Shuttle, Partenariat, Ministère de l'Économie et de l'Innovation, Programme de soutien aux organismes de recherche et d’innovation (PSO) - Volet 1 : Soutien au fonctionnement d'organisme (Ancien PSVT), from 2018-10-22 to 2019-10-21
  • Financement pour la formation d'une étudiante au doctorat, Subvention, Fondation du CHU de Québec, from 2019-06-17 to 2020-03-31
  • Interactions non-covalentes pour l'isolation des nanoparticules, Subvention, Fonds de recherche du Québec - Nature et technologies, Établissement de la relève professorale, from 2018-04-01 to 2020-03-31
  • Profil toxicologique de nanosphères de silice comme vecteur pharmaceutique, Partenariat, Ministère de l'Économie et de l'Innovation, Programme de soutien aux organismes de recherche et d’innovation (PSO) - Recherche-innovation - Volet 2a, from 2019-10-01 to 2020-03-31
Data provided by the Université Laval research projects registery